Compare RELY & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | IMNM |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2021 | 2020 |
| Metric | RELY | IMNM |
|---|---|---|
| Price | $17.12 | $22.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $24.13 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.16 | 51.40 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,635,147,000.00 | $6,941,000.00 |
| Revenue This Year | $21.89 | N/A |
| Revenue Next Year | $19.17 | $1,127.34 |
| P/E Ratio | $54.44 | ★ N/A |
| Revenue Growth | ★ 29.37 | N/A |
| 52 Week Low | $12.08 | $6.97 |
| 52 Week High | $24.63 | $27.65 |
| Indicator | RELY | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 57.23 |
| Support Level | $16.75 | $19.23 |
| Resistance Level | $17.81 | $22.86 |
| Average True Range (ATR) | 0.60 | 1.17 |
| MACD | 0.12 | 0.25 |
| Stochastic Oscillator | 100.00 | 86.31 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated from transaction fees charged to customers, and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.